Executive record
Annette Marleau
Public governance roles and source-backed Claims for this individual.
More
Alpha ID: alpha:person:annette-marleauVersion: public-0As of: 2026-10-01
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Dr. Marleau became Chief Scientific Officer on April 1, 2023. Receives annual base salary of $300,000 with automatic 3% annual increases plus bonus compensation not to exceed 40% of salary.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Board service coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageExecutive career
- 2025 to end not publishedExecutive title: Chief Scientific Officer · Organization not publishedSIGY 10-K executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
SIGY 10-K executive officers
sec filing · Source published: Apr 15, 2025 · Retrieved: May 16, 2026
Supports 5 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at Sigyn Therapeutics, Inc. · Claim reviewed: May 16, 2026
- Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 16, 2026
- Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01
- Biography
- published
- Board service
- not observed
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope